PBM reform is here. What do new transparency and fiduciary rules mean for the industry? Federal legislation, new state laws and proposed reforms are placing pharmacy benefit managers under growing scrutiny.
Managed Healthcare Executive® partnered with Drug Topics® on a timely webinar, PBMs, Transparency and Fiduciary Responsibility, examining how emerging PBM transparency requirements, fiduciary responsibilities and policy reforms could reshape relationships among payers, pharmacies and PBMs.
Watch the recorded discussion now to hear expert perspectives on the evolving regulatory landscape and what these policy changes may mean for managed care strategy and pharmacy benefit operations.
Eli Lilly released phase 2b trial results comparing the investigational eloralintide-tirzepatide combo with tirzepatide 15 mg alone in patients with T2D and obesity.
Highlighting the clinical impact of the pharmacy profession, we caught up with pharmacists of various types to get their perspectives on the evolution of pharmacy.
Rita King, CEO of MethodSense, provides her expertise on the integration of AI in medical devices and key developments for pharmacists as the technology evolves.